Treatment of Inoperable Hepatocellular Carcinoma With Intrahepatic Arterial Yttrium-90 Microspheres: A Phase I and II Study

British Journal of Cancer- United Kingdom

doi 10.1038/bjc.1994.436

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Radioembolisation With Yttrium‒90 Microspheres Versus Sorafenib for Treatment of Advanced Hepatocellular Carcinoma (SARAH): Study Protocol for a Randomised Controlled Trial

Trials
MedicinePharmacology
2014English

Yttrium-90 Radioembolization Versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Comparative Analysis

HPB
HepatologyGastroenterology
2016Romanian

Management of a Duodenobronchial Fistula After Yttrium 90 Transarterial Radioembolization in a Patient With Recurrent Hepatocellular Carcinoma

HPB
HepatologyGastroenterology
2018English

A Clinical Phase II Study of Sorafenib in Advanced Hepatocellular Carcinoma

Anaplastology
2012English

Selective Intraarterial Radionuclide Therapy With Yttrium-90 (Y-90) Microspheres for Unresectable Primary and Metastatic Liver Tumors

World Journal of Surgical Oncology
SurgeryOncology
2011English

A Comparative Study Hepatectomy With Transcatheter Arterial Embolization for Treatment of 102cases of Hepatocellular Carcinoma.

Japanese Journal of Gastroenterological Surgery
SurgeryGastroenterology
1987English

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2016English

Gemcitabine Plus Carboplatin in Patients With Advanced Hepatocellular Carcinoma: Results of a Phase II Study

ISRN Oncology
2012English

A Phase II Study of Cixutumumab (IMC-A12, NSC742460) in Advanced Hepatocellular Carcinoma

Journal of Hepatology
Hepatology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy